

## Nine-month figures for 2008

€ in millions Unaudited figures	Nine-month 2008	Nine-month 2007 pro forma	Growth in %	Growth in %, const. currencies
Sales revenue	275.0	281.8	-2.4%	+1.6%
• Europe <sup>1)</sup>	169.5	160.4	+5.7%	+7.3%
• North America <sup>1)</sup>	59.5	74.9	-20.6%	-10.4%
• Asia   Pacific <sup>1)</sup>	37.2	37.5	-0.8%	+2.1%
• Other Markets <sup>1)</sup>	8.8	9.0	-1.6%	-1.3%
EBITA <sup>2)</sup>	29.8	35.2		
EBITA margin <sup>2)</sup>	10.8%	12.5%		
Net profit <sup>2)3)</sup>	13.9	18.3		

<sup>1)</sup> According to customers' location

<sup>2)</sup> For 2007: underlying

<sup>3)</sup> Excluding amortization

Sartorius Stedim Biotech S.A.  
 Z.I. des Paluds  
 Avenue de Jouques  
 B.P. 1051  
 13781 Aubagne - France  
[www.sartorius-stedim.com](http://www.sartorius-stedim.com)

Press Contact:  
 Petra Kirchoff  
 Phone +49 (0)551.308.1686

Goettingen, October 28, 2008

### Persistently difficult market environment in the US

Especially because of the persistently difficult market situation in North America sales revenue for the Sartorius Stedim Biotech Group (SSB) was below forecast. In Europe sales revenue growth showed solid development, but was impacted by fluctuations in the equipment business. Growth in Asia evolved at moderate rates. Given the overall weak market situation, SSB performed well, also when compared to the competition.

### Solid profitability

Although overall growth was not satisfactory, Sartorius Stedim Biotech achieved a robust EBITA margin of 10.8%, based on its strong business model and well-managed cost structure. In constant currencies, the company's EBITA margin is nearly one percentage point higher.

### Product launches on track

Throughout 2008, the company has been introducing a large number of new, innovative products, especially for single-use applications. Products launched so far have been well received on the markets, and remaining launches are on track.

### Strong financial position

Reflected by an equity ratio of 56.9% and gearing of 0.4, the financial position of the Sartorius Stedim Biotech Group remains strong.

### Outlook for 2008

Due to the increasingly difficult and uncertain global economic conditions, SSB does not consider it possible to make a reliable quantitative forecast about the fourth quarter. Nevertheless, management does expect that the overall stable development of the first three quarters will continue on into the following months. For the fourth quarter, SSB anticipates a robust operating result and significantly positive operating cash flows. However, it is not expected that the full-year targets published in the First-Half Financial Report will be reached. Besides this, the highly positive mid-term prospects for the biopharmaceutical industry and SSB as one of their leading suppliers remain unchanged.

## Conference Call and Webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors today, October 28, 2008, at 3:00 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 2:45 p.m. CET at the following numbers:

Germany: +49 (0) 69 2222 2220;

France: +33 (0) 1 70 99 42 82;

UK: +44 (0) 20 7138 0839;

USA: +1 718 354 1362.

The dial-in code is: 4944170; to view the webcast, log onto <http://www.sartorius.com> or <http://www.livemeeting.com/cc/premconfeurope/join?id=4944170&role=attend&pw=pw4329>

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

## A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2007 generated pro forma sales revenue of 375.9 million euros.

---

**Contact:** Petra Kirchhoff; Vice President of Communications;  
Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany;  
Phone: +49(0)551/ 308-1686; Fax: +49(0)551/ 308-3410; e-mail:  
[petra.kirchhoff@sartorius.com](mailto:petra.kirchhoff@sartorius.com); <http://www.sartorius.com> or  
Press-Service: <http://www.sartorius.de/presse.html>